Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
DEBORAH M HINTON · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2020 · $355,031 — Nearly all virulence factors in Bordetella pertussis are activated by a master two-component system, BvgAS, composed of the sensor kinase BvgS and the response regulator BvgA. When BvgS is active, BvgA is phosphorylated (BvgAP), and virulence activated genes are expressed (the Bvg(+) mode). When B…
Jeffrey Cohen · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $947,827 — Herpes simplex virus 2 (HSV-2) causes genital herpes and increases the risk of transmission and infection with HIV. Thus a vaccine for HSV-2 would not only reduce the rate of genital herpes, but also might reduce spread of HIV. Several HSV-2 vaccines have been tested in humans for prevention or redu…
BARBARA K FELBER · DIVISION OF BASIC SCIENCES - NCI · 2020 · $1,866,900 — An ideal HIV vaccine should provide protection against all HIV-1 variants. Thus, an important aspect of HIV vaccine development is the selection of immunogens, which has to take into consideration the diversity of the different HIV clades and the identification of the critical epitopes able to induc…
Elizabeth Conner · DIVISION OF BASIC SCIENCES - NCI · 2020 · $1,642,585 — CCR Genomics Core lists over 1040 registered members in its iLab management and scheduling software with 270 research groups of which 192 are from NCI and the remaining 77 from 13 other NIH institutes. These institutes include NIAID, NHGRI, NEI, NINDS, NHLBI, NIAMS, NIDDK, NIMH, NIA, NIAAA, NIDCD, N…
LOUISE C. SHOWE · WISTAR INSTITUTE · 2020 · $205,228 — PROJECT SUMMARY – GENOMICS SHARED RESOURCE The Genomics Shared Resource (GSR) provides state-of-the-art infrastructure and support for integrated functional genomics studies of Cancer Center (CC) investigators. The highly trained staff and their efforts to maintain costs without diminishing service,…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $942,168 — Vaccine trials in non-human primates challenged with R5, tier 2 SHIVs have shown protection in the presence of high levels of non-neutralizing antibodies (NNAbs), and one of the 5 Phase IIb HIV-1 vaccine efficacy trials using alum (ALVAC/AIDSVAX in RV144) showed an estimated vaccine efficacy of 31%,…
GARRY P NOLAN · STANFORD UNIVERSITY · 2020 · $306,812 — PROJECT SUMMARY New technologies such as mass cytometry have greatly expanded our ability to deepen our understanding of the complexity of lymphocytes and related populations. The Stanford CCHI group has been particularly attuned to the potential in following the lead of the Nolan lab in exploiting …
Barney Graham · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $3,038,369 — Improvements in vaccines against influenza that increase potency, breadth and durability of protection would improve worldwide ability to combat seasonal changes in influenza viruses (drift) and emergence of new pandemic strains (shift). This study aims to develop new platforms and vaccination strat…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2020 · $686,141 — Project Summary Administrative Core This Phase II COBRE will continue our center’s work to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approaches for unde…
SILVIA GRAMA · NANOCOMPOSIX, INC. · 2020 · $300,000 — Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen …
FANG LIU · ZYMERON CORPORATION · 2020 · $300,000 — Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen …
DAVID MCCORMICK · IIT RESEARCH INSTITUTE · 2020 · $430,361 — PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER…
JULIE AKE · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $22,000,000 — The NIAID Division of AIDS and the U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research (WRAIR), U.S. Army Medical Research and Development Command (MRDC) remain committed to the common objective of developing a safe and effective vaccine for HIV/AIDS. The Agencies recog…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $871,042 — Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages A major goal of HIV-1 vaccine development is to induce broadly neutralizing antibodies (bnAbs). This IPCAVD team has immunogens that can trigger unmutate…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $203,809 — The overall goals of the Animal Models Core is to support all programs of the IPCAVD by performing immunization studies in DH270 unmutated common ancestor (UCA) VH + VL knock-in (KI) mice with V3- Man9 glycopeptide primes and modified mRNA boosts (Project 1, Aim 2), by performing immunization studie…
Sallie R. Permar · DUKE UNIVERSITY · 2020 · $244,720 — ABSTRACT – Project 1 There is a critical need to protect adolescents and young adults from HIV infection through the development of an early life vaccine strategy that elicits protective immunity prior to sexual debut. However, to date, efforts to develop a vaccine that can elicit protective broadly…
STANLEY FIELDS · UNIVERSITY OF WASHINGTON · 2020 · $312,822 — Project Summary In TR&D 1, we develop approaches to make complex changes to cells, and we generate biosensors to report on the effects of some of these changes. In the first aim, we establish strategies to rapidly and combinatorially up- or down-regulate a set of genes in a common pathway in order t…
Genevieve Giny Fouda Amou ou · DUKE UNIVERSITY · 2020 · $546,751 — ABSTRACT – Project 2 Globally, about 600,000 young adults (15-24 years of age) became infected with HIV-1 in 2017. Young women age 15-19 years are most affected, and HIV-infection in this age group continue to rise. Therefore, a vaccine to prevent HIV acquisition in young adults remains a top priori…
Joanna Phillips · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $180,622 — PROJECT SUMMARY The UCSF Brain Tumor SPORE Biospecimen/Pathology Core provides staff and technology dedicated to the procurement, processing, storing, distribution, and histopathologic analysis of high-quality brain tumor biospecimens for translational science research. Our mission is to enhance bio…
Introduction to MenQuadfi Label Change for Infants Sarah Schillie, MD, MPH, MBA Advisory Committee on Immunization Practices April 16, 2025National Center for Immunization & Respiratory Diseases 1 The findings and conclusions in this report are those of the authors and do not necessarily represent the official position o f the U. S. Centers for Disease Control and Prevention. MenACWY Vaccines Available for Use in the United States* Manufacturer Trade Name AbbreviationLicensed Age…